Abstract
The insulin-like growth factor (IGF) axis plays an important role in mammary gland physiology. In addition, dysregulation of this molecular axis may have a causal role in the aetiology and development of breast cancer (BC). This report discusses the IGF axis in normal and neoplastic mammary gland with special reference to IGF binding proteins (IGFBPs) -2 and −5. We describe how these high affinity binders of IGF-1 and IGF-2 may regulate local actions of growth factors in an autocrine and/or paracrine manner and how they also have IGF-independent effects in mammary gland. We discuss clinical studies which investigate both the prognostic value of IGFBP-2 and −5 expression in BC and possible involvement of these genes in the development of resistance to adjuvant endocrine therapies.
Similar content being viewed by others
References
Ahmed SR et al (1990) Characterization and hormonal regulation of radioimmunoassayable IGF-I (insulin-like growth factor I) like activity and IGF-binding proteins secreted by human breast cancer cells. Anticancer Res 10(5A):1217–1223
Ahn BY et al (2010) Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer. Cancer Res 70(8):3013–3019
Akkiprik M et al (2009) The subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer. BMC Cancer 9:103
Allander SV et al (1994) Characterization of the chromosomal gene and promoter for human insulin-like growth factor binding protein-5. J Biol Chem 269(14):10891–10898
Amaar YG et al (2002) Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2). J Biol Chem 277(14):12053–12060
Amaar YG, Baylink DJ, Mohan S (2005) Ras-association domain family 1 protein, RASSF1C, is an IGFBP-5 binding partner and a potential regulator of osteoblast cell proliferation. J Bone Miner Res 20(8):1430–1439
Arai T et al (1994) Glycosaminoglycans inhibit degradation of insulin-like growth factor-binding protein-5. Endocrinology 135(6):2358–2363
Arteaga CL et al (1989) Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84(5):1418–1423
Beattie J et al (2006) Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 395(1):1–19
Becker MA et al (2012) IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res 18(6):1808–1817
Belfiore A, Frasca F (2008) IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13(4):381–406
Boylan M, van den Berg HW, Lynch M (1998) The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen. Ann Oncol 9(2):205–211
Busund LT et al (2005) Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 58(4):361–366
Butt AJ et al (2003) Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 278(32):29676–29685
Butt AJ et al (2005) Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology 146(7):3113–3122
Cheng HL, Shy M, Feldman EL (1999) Regulation of insulin-like growth factor-binding protein-5 expression during Schwann cell differentiation. Endocrinology 140(10):4478–4485
Clarkson RW, Watson CJ (2003) Microarray analysis of the involution switch. J Mammary Gland Biol Neoplasia 8(3):309–319
Clemmons DR (2007) Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6(10):821–833
Coutts A, Murphy LJ, Murphy LC (1994) Expression of insulin-like growth factor binding proteins by T-47D human breast cancer cells: regulation by progestins and antiestrogens. Breast Cancer Res Treat 32(2):153–164
Cullen KJ et al (1992) Insulin-like growth factor expression in breast cancer epithelium and stroma. Breast Cancer Res Treat 22(1):21–29
De Leon DD et al (1988) Demonstration of insulin-like growth factor (IGF-I and -II) receptors and binding protein in human breast cancer cell lines. Biochem Biophys Res Commun 152(1):398–405
De Leon DD et al (1989) Characterization of insulin-like growth factor binding proteins from human breast cancer cells. Mol Endocrinol 3(3):567–574
De Leon DD et al (1990) Insulin-like growth factor binding proteins in human breast cancer cells: relationship to hIGFBP-2 and hIGFBP-3. J Clin Endocrinol Metab 71(2):530–532
Dean SJ et al (2014) Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer. Am J Clin Pathol 141(3):323–333
Disis ML et al (2013) A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila) 6(12):1273–1282
Dokmanovic M et al (2011) Trastuzumab regulates IGFBP-2 and IGFBP-3 to mediate growth inhibition: implications for the development of predictive biomarkers for trastuzumab resistance. Mol Cancer Ther 10(6):917–928
Dubois V et al (1995) Intracellular levels and secretion of insulin-like-growth-factor-binding proteins in MCF-7/6, MCF-7/AZ and MDA-MB-231 breast cancer cells. differential modulation by estrogens in serum-free medium. Eur J Biochem 232(1):47–53
Foulstone EJ et al (2013) Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor. Endocrinology 154(5):1780–1793
Frommer KW et al (2006) IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol 37(1):13–23
Garner CP et al (2008) Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet 123(3):247–255
Ghoussaini M et al (2014) Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nat Commun 4:4999
Hadsell DL, Baumrucker CR, Kensinger RS (1993) Effects of elevated blood insulin-like growth factor-I (IGF-I) concentration upon IGF-I in bovine mammary secretions during the colostrum phase. J Endocrinol 137(2):223–230
Hao X et al (2004) Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 100(6):1110–1122
Huff KK et al (1986) Secretion of an insulin-like growth factor-I-related protein by human breast cancer cells. Cancer Res 46(9):4613–4619
Huynh H (1998) In vivo regulation of the insulin-like growth factor system of mitogens by human chorionic gonadotropin. Int J Oncol 13(3):571–575
Huynh H, Yang XF, Pollak M (1996) A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ 7(11):1501–1506
Juncker-Jensen A et al (2006) Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res 16(4):224–239
Knowlden JM et al (2005) Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 146(11):4609–4618
Li X et al (2007) Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci 98(10):1592–1596
Lochrie JD et al (2006) Insulin-like growth factor binding protein (IGFBP)-5 is upregulated during both differentiation and apoptosis in primary cultures of mouse mammary epithelial cells. J Cell Physiol 207(2):471–479
Manni A et al (1994) Hormonal regulation of insulin-like growth factor II and insulin-like growth factor binding protein expression by breast cancer cells in vivo: evidence for stromal epithelial interactions. Cancer Res 54(11):2934–2942
Marshman E et al (2003) Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells. J Cell Sci 116(Pt 4):675–682
Martin JL, Baxter RC (2007) Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology 148(5):2532–2541
Massarweh S et al (2006) Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66(16):8266–8273
Maxwell P, van den Berg HW (1999) Changes in the secretion of insulin-like growth factor binding proteins −2 and −4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. Cancer Lett 139(2):121–127
McCaig C, Perks CM, Holly JM (2002) Signalling pathways involved in the direct effects of IGFBP-5 on breast epithelial cell attachment and survival. J Cell Biochem 84(4):784–794
McCotter D et al (1996) Changes in insulin-like growth factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro. Cancer Lett 99(2):239–245
McGrath MF et al (1991) The direct in vitro effect of insulin-like growth factors (IGFs) on normal bovine mammary cell proliferation and production of IGF binding proteins. Endocrinology 129(2):671–678
McGuire WL Jr et al (1992) Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84(17):1336–1341
McGuire SE et al (1994) Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett 77(1):25–32
Minuto F et al (1987) Partial characterization of somatomedin C-like immunoreactivity secreted by breast cancer cells in vitro. Mol Cell Endocrinol 54(2–3):179–184
Mireuta M, Darnel A, Pollak M (2010) IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 28(4):243–255
Mita K et al (2007) Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol 37(8):575–582
Osborne CK, Clemmons DR, Arteaga CL (1990) Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol 37(6):805–809
Parisot JP et al (1999a) Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line. Breast Cancer Res Treat 55(3):231–242
Parisot JP et al (1999b) Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 79(5–6):693–700
Park KH et al (2008) Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 68(20):8400–8409
Pekonen F et al (1992) Insulin-like growth factor binding proteins in human breast cancer tissue. Cancer Res 52(19):5204–5207
Pereira JJ et al (2004) Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 64(3):977–984
Perks CM et al (1999) Differential IGF-independent effects of insulin-like growth factor binding proteins (1–6) on apoptosis of breast epithelial cells. J Cell Biochem 75(4):652–664
Perks CM et al (2002) Effects of a non-IGF binding mutant of IGFBP-5 on cell death in human breast cancer cells. Biochem Biophys Res Commun 294(5):995–1000
Perks CM et al (2007) IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 26(40):5966–5972
Phillips K et al (2003) Hormonal control of IGF-binding protein (IGFBP)-5 and IGFBP-2 secretion during differentiation of the HC11 mouse mammary epithelial cell line. J Mol Endocrinol 31(1):197–208
Plant HC et al (2014) Differential subcellular and extracellular localisations of proteins required for insulin-like growth factor- and extracellular matrix-induced signalling events in breast cancer progression. BMC Cancer 14:627
Pollak MN (1998) Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47(3):209–217
Rotwein P, James PL, Kou K (1995) Rapid activation of insulin-like growth factor binding protein-5 gene transcription during myoblast differentiation. Mol Endocrinol 9(7):913–923
Rozen F, Pollak M (1999) Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol 15(3):589–594
Rudolph MC et al (2003) Functional development of the mammary gland: use of expression profiling and trajectory clustering to reveal changes in gene expression during pregnancy, lactation, and involution. J Mammary Gland Biol Neoplasia 8(3):287–307
Schedlich LJ et al (1998) Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 273(29):18347–18352
Schutt BS et al (2004) Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 32(3):859–868
Sehgal P et al (2013) Regulation of protumorigenic pathways by insulin like growth factor binding protein2 and its association along with beta-catenin in breast cancer lymph node metastasis. Mol Cancer 12:63
Sheikh MS et al (1992) Identification of the insulin-like growth factor binding proteins 5 and 6 (IGFBP-5 and 6) in human breast cancer cells. Biochem Biophys Res Commun 183(3):1003–1010
So AI et al (2008) Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14(21):6944–6954
Soh, C.L., et al., Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer. Br J Cancer, 2014.
Sureshbabu A et al (2012) IGFBP5 induces cell adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells. J Cell Sci 125(Pt 7):1693–1705
Taylor KJ et al (2010) Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer. Breast Cancer Res 12(3):R39
Tonner E et al (1997) Hormonal control of insulin-like growth factor-binding protein-5 production in the involuting mammary gland of the rat. Endocrinology 138(12):5101–5107
Tonner E et al (2000) Insulin-like growth factor binding protein-5 (IGFBP-5) potentially regulates programmed cell death and plasminogen activation in the mammary gland. Adv Exp Med Biol 480:45–53
Tonner E et al (2002) Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. Development 129(19):4547–4557
van den Berg HW et al (1996) Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br J Cancer 73(4):477–481
Vijayan A et al (2013) IGFBP-5 enhances epithelial cell adhesion and protects epithelial cells from TGFbeta1-induced mesenchymal invasion. Int J Biochem Cell Biol 45(12):2774–2785
Wang H et al (2008) IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J 14(3):261–267
Wiseman LR et al (1993) Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur J Cancer 29A(16):2256–2264
Wood TL et al (2000) The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia 5(1):31–42
Yamashita H et al (2009) Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100(11):2028–2033
Yee D et al (1988) Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48(23):6691–6696
Yee D et al (1989) Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3(3):509–517
Zeng L, Holly JM, Perks CM (2014) Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells. Front Endocrinol (Lausanne) 5:61
Acknowledgments
King Faisal Specialist Hospital & research Centre—Jeddah (KFSH&RC-Jed) YH, the King AbdulAziz University –Jeddah (KAAU) HA. RE acknowledges WELMEC, a Centre of Excellence in Medical Engineering funded by the Wellcome Trust and EPSRC, under grant number WT 088908/Z/09/Z for financial support. HA and YH acknowledge the Royal Embassy of Saudi Arabia – Cultural Bureau (UK) for financial support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beattie, J., Hawsawi, Y., Alkharobi, H. et al. IGFBP-2 and −5: important regulators of normal and neoplastic mammary gland physiology. J. Cell Commun. Signal. 9, 151–158 (2015). https://doi.org/10.1007/s12079-015-0260-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12079-015-0260-3